Overcoming Compounding's Dark Side July 21 2012| Filed

New Post Public Reply Private Reply Replies (0) Message Board
NITE

Overcoming Compounding's Dark Side
July 21 2012| Filed Under » Financial Theory, Interest Rates, Investing Basics, Portfolio Management, Stocks
Contrary to what we are led to believe, investors can only spend compound returns, not average returns. Nevertheless, the average returns are so often mentioned by those seeking to promote an investment approach. This practice can often mislead investors who don't understand how money is made and lost over a period of time, due to compounding, in markets that move up in one year and down in the next.

SEE: Accelerating Returns With Continuous Compounding

There are two factors that can have a significant impact on the realized returns experienced by investors: the dispersion of returns and the impact of negative returns. Read on to discover the impact these factors could have on your portfolio, and how you can use this knowledge to gain higher compound returns and avoid the negative side of compounding.

Back to Basics
First, let's review the mathematics used to calculate simple and compound averages. The simple return is the mathematical average of a set of numbers. The compound return is a geometric mean, or the single percentage, usually annual, that provides the cumulative effect of a series of returns. The compound return is the mathematical calculation describing the ability of an asset to generate earnings (or losses) that are then reinvested and generate their own earnings (or losses).
Let's say you invested $1,000 in the Dow Jones Industrial Average (DJIA ) in 1900. The average annual return between 1900 and 2005 for the DJIA is 7.3%. Using the annual average of 7.3%, an investor has the illusion that $1,000 invested in 1900 would become $1,752,147 at the end of 2005 because $1,000 compounded annually at 7.3% yields $1,752,147 by the end of 2005.

However, the DJIA was 66.08 at the beginning of 1900 and it ended at 10717.50 in 2005. This results in a compound average of 4.92%. In the market, you only receive compound returns, so $1,000 invested at the beginning of 1900 in the DJIA would result in only $162,547 by the end of 2005. (To keep things simple and relevant to the discussion, dividends, transaction costs and taxes have been excluded.)

What happened? There are two factors that contribute to the lower results from compounding: dispersion of returns around the average and the impact of negative numbers on compounding.

SEE: Using Historical Volatility To Gauge Future Risk

Dispersion of Returns
As the returns in a series of numbers become more dispersed from the average, the compound return declines. The greater the volatility of returns, the greater the drop in the compound return. Some examples will help to demonstrate this. Figure 1 shows five examples of how the dispersion of returns impacts the compound rate.

The first three examples show positive or, at worst, 0% annual returns. Notice how in each case, while the simple average is 10%, the compound average declines as the dispersion of returns widens. However, half the time the stock market moves up or down by 16% or more in a year. In the last two examples, there were losses in one of the years. Note that as the dispersion in returns grows wider, the compound return gets smaller, while the simple average remains the same.

Figure 1

This wide dispersion of returns is a significant contributor to the lower compound returns investors actually receive.

Impact of Negative Returns
It is obvious that negative returns hurt the actual returns realized by investors. Negative returns also significantly impact the positive impact compounding can have on your total return. Again, some examples will demonstrate this problem.
Looking for penny stocks that skyrocket?
In each of the examples in Figure 2, a loss is experienced in one year and the compound average return for the two years is negative. Of particular importance is the percent return required to break even after the loss. As the loss increases, the return required to break even grows significantly as a result of the negative effect of compounding.

Figure 2

Another way to think about the impact of negative returns on compounding is to answer this question, "What if you invested $1,000 and in the first year you earned 20%, and then lost 20% the following year?" If this up and down cycle continued for 20 years, it would create a situation that is not that different from what occurs in the market. How much would you have at the end of 20 years? The answer is a disappointing $664.83 - not exactly something to brag about next time you're at a party.

The impact of dispersion of returns and negative numbers can be deadly to your portfolio. So, how can an investor overcome the dark side of compounding and achieve superior results? Fortunately, there are techniques to make these negative factors work for you.

SEE: How To Calculate Your Investment Return

Overcoming the Dark Side of Compounding
Successful investors know that they must harness the positive power of compounding while overcoming its dark side. Like so many other strategies, this requires a disciplined approach and homework on the part of the investor.

As academic and empirical research has shown, some of a stock's price movements are due to the general trend of the market. When you are on the right side of the trend, compounding works for you, both in up markets as well as down markets. Therefore, the first step is to determine whether the market is in a secular (long-term or multi-year) bull or bear trend. Then invest with the trend. This also holds true for shorter term trends that take place within the secular trends.

SEE: The Utility Of Trendlines

During bull markets it is fairly easy to do well - the common quip is correct, "a rising tide floats all boats." However, during a bear or flat market, different stocks will perform well at different times. In these environments, winning investors seek stocks that offer the best absolute returns in strong sectors. Investors must become good stock pickers rather than just investing in a diversified portfolio of stocks. In such cases, using the value approach to investing can have excellent results. It can also be useful to learn to short the market when the trend is down. Another strategy is to use bonds to build a ladder that provides a relatively safe return that can be used in a weak stock market environment.
During weak markets, when negative compounding can substantially harm your portfolio, it is even more important to employ proven capital management techniques. This starts with trailing stops to minimize losses and/or capture some profit from an investment. Another important technique is to rebalance your portfolio more frequently. Rebalancing capitalizes on short-term cycles in the financial markets. By selling part or all of the top performers in one asset class or sector, it provides capital to invest in new promising opportunities. A variation of this strategy is to sell part of your position when you have a quick gain to capture some profit and move the stop to or above your entry price. In every case, the investor is actively seeking to offset the negative side of compounding or even work with it.

The Bottom Line
Overcoming the dark side of compounding requires that an investor be an active manager of his or her portfolio. This requires learning the skills needed to recognize market trends, find appropriate investment opportunities and then employ proven capital management techniques. Overcoming the negative side of compounding and beating the market can a very satisfying experience, after all, it's your money that's at stake.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 3

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Updated Category News Views 4

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 3

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
TrailBlazer Magazine Snags a Tribune for In-House Design

Updated Category News Views 4

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

Continue Reading
MMRO Achieves URAC AI Accreditation, Ensures Compliance

Updated Category News Views 4

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming the Narcolepsy Market: Innovations Ahead

Updated Category News Views 166

The Evolving Landscape of the Narcolepsy Market The narcolepsy market is undergoing significant changes as it shifts from merely managing symptoms to developing targeted therapies that tackle the root causes of the disorder. Traditionally, treatments focused on alleviating symptoms, but advancements now emphasize addressing the underlying neurochemical issues, primarily...

Continue Reading
UBS Analysts Share Insights on China Stocks Strategies

Updated Category News Views 242

UBS Analysts Offer Insights on China's Equity Market In a recent discussion, UBS strategists have expressed a level of caution regarding China's equity market as they look into the evolving landscape of 2025. It's noted that local A-share investors appear hesitant to seize buying opportunities, influenced by a myriad of factors that create uncertainty in the market....

Continue Reading
Palisade Bio's Special Meeting Cancellation: What You Need to Know

Updated Category News Views 133

Palisade Bio Cancels Special Meeting of Stockholders Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company making strides in developing innovative treatments for autoimmune, inflammatory, and fibrotic diseases. Recently, the company announced an important decision regarding its special meeting of stockholders. The special meeting, originally...

Continue Reading
Vivendi Reports Impressive 4.5% Revenue Growth in 2024

Updated Category News Views 123

Remarkable Revenue Growth for Vivendi Vivendi has announced an impressive increase in its revenues for the first nine months of 2024, emphasizing strong growth across its core business sectors. The company reported a revenue increase of 4.5% at constant currency and perimeter, compared to the same period in the previous year. This growth showcases the resilience and...

Continue Reading
Revolution in Home Renovation Arrives with Spray-Net Franchise

Updated Category News Views 226

Fresh Approach to Home Makeovers Home remodeling isn’t just about slapping on a new coat of paint anymore. In February 2026, Spray-Net is gearing up to launch in Allen, Texas, shaking things up in the renovation game. This venture represents a leap forward—not only for franchise growth but for homeowners who are sick and tired of traditional, drawn-out renovations....

Continue Reading